Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Other (2016 - 2023)

Historic Receivables - Other for Spyre Therapeutics (SYRE) over the last 6 years, with Q1 2023 value amounting to $330000.0.

  • Spyre Therapeutics' Receivables - Other fell 6739.13% to $330000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $330000.0, marking a year-over-year decrease of 6739.13%. This contributed to the annual value of $375000.0 for FY2022, which is N/A changed from last year.
  • Spyre Therapeutics' Receivables - Other amounted to $330000.0 in Q1 2023, which was down 6739.13% from $375000.0 recorded in Q4 2022.
  • Over the past 5 years, Spyre Therapeutics' Receivables - Other peaked at $1.0 million during Q1 2022, and registered a low of $330000.0 during Q1 2023.